QIAGEN N.V. Overview
Industry: Diagnostics & Research
Sector: Healthcare
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for geno Read MoreMavefund brings filings, fundamentals, valuation, price history and news for QIAGEN N.V. into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net sales was $492M (reported); EPS was $0.33 (reported).
Net sales
$492M
reported
EPS
$0.33
reported
Operating income
$84M
reported
Free cash flow
$54M
reported
What changed
- Net sales reported to $492M; EPS reported to $0.33.
- Capital return update: free cash flow $54M.
- Operating income: Operating income was $84 million compared to $115 million in Q1 2025. Adjusted operating income, which excludes various charges and other items in both periods, declined 7% to $135 million. The adjusted operating income margin was 27.4% of sales compared with 29.8% in Q1 2025, reflecting investments in Parse following the November 2025 acquisition and headwinds from tariffs and adverse currency movements that were partially offset by efficiency gains and cost discipline. The adjusted gross margin was 66.1% compared with 67.4% in the prior-year period, primarily due to tariffs. Sales and marketing expenses increased to 23.3% of sales from 22.0% in Q1 2025, in part due to Parse investments, while general and administrative expenses declined to 5.6% from 6.5% in the year-ago period. 2.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
KKR (KKR) After Qiagen Interest And Allyntra Launch Has Valuation Back In Focus
Headline from Yahoo Finance: KKR (KKR) After Qiagen Interest And Allyntra Launch Has Valuation Back In Focus.
KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen
Headline from Yahoo Finance: KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen.
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak
Headline from Investing.com: Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak.
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak By Investing.com
Headline from Investing.com South Africa: Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak By Investing.com.
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
Headline from Yahoo Finance: QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak.
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
Headline from Yahoo Finance: QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast.
Earnings Per Share
Score 2.00/5
QIAGEN N.V. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Agilent Technologies Inc
, Thermo Fisher Scientific Inc
are companies with high ratings.
Return on Equity
Score 3.37/5
QIAGEN N.V. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.84/5
QIAGEN N.V.
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.92/5
QIAGEN N.V.
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios